Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Zivo Bioscience Inc. has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners and 4 distinct art units. NGUYEN, NGHI V is the busiest examiner, responsible for 1 pending office action. The one-to-one ratio of actions to examiners and art units indicates a broad technical spread for this company patent portfolio.
Because there are 4 pending office actions and 4 distinct examiners, the company must navigate 4 different sets of examiner preferences. The fact that these are also spread across 4 distinct art units indicates that the portfolio's technical scope is wide within the biotechnology field. Practitioners cannot rely on a single art unit's trends or a single examiner's history to predict outcomes. Instead, they must develop a tailored approach for each of the 4 pending office actions. This high level of dispersion across the patent office requires a sophisticated management strategy to ensure consistency across such a varied technical and administrative landscape. No single examiner, including NGUYEN, NGHI V, has a dominant influence over the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, NGHI V | 1 | 53.6% | +50.8% |
| DURYEE, ALEXANDER MARSH | 1 | 33.3% | +41.7% |
| XU, QING | 1 | 50.9% | +55.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17410016 | NATURAL FEED COMPOSITION DERIVED FROM FRESH WATER ALGAL CULTURES FOR THE PROMOTION OF ANIMAL GROWTH | XU, QING | 58d overdue |
| 18988752 | ALGORIPHAGUS SP, BOSEA SP, BREVUNDIMONAS SP, DESULFOVIBRIO SP, MICROBACTERIUM SP, SPHINGOMONAS SP, AND VARIOVORAX SP FOR USE IN DISEASE PREVENTION AND TREATMENT | NGUYEN, NGHI V | — |
| 17587582 | MATURATION OF IMMUNE AND METABOLIC PROCESSES VIA ALGAL BIOMASS AND/OR RELATED MATERIAL ADMINISTERED TO ANIMALS | DURYEE, ALEXANDER MARSH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17410016 | NATURAL FEED COMPOSITION DERIVED FROM FRESH WATER ALGAL CULTURES FOR THE PROMOTION OF ANIMAL GROWTH | XU, QING | 58d overdue |
| 18988752 | ALGORIPHAGUS SP, BOSEA SP, BREVUNDIMONAS SP, DESULFOVIBRIO SP, MICROBACTERIUM SP, SPHINGOMONAS SP, AND VARIOVORAX SP FOR USE IN DISEASE PREVENTION AND TREATMENT | NGUYEN, NGHI V | — |
| 17587582 | MATURATION OF IMMUNE AND METABOLIC PROCESSES VIA ALGAL BIOMASS AND/OR RELATED MATERIAL ADMINISTERED TO ANIMALS | DURYEE, ALEXANDER MARSH | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1657 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18988752 | ALGORIPHAGUS SP, BOSEA SP, BREVUNDIMONAS SP, DESULFOVIBRIO SP, MICROBACTERIUM SP, SPHINGOMONAS SP, AND VARIOVORAX SP FOR USE IN DISEASE PREVENTION AND TREATMENT | NGUYEN, NGHI V | 1653 | §103§112 | Non-Final OA | — | Pending | Dec 19, 2024 |
| 17587582 | MATURATION OF IMMUNE AND METABOLIC PROCESSES VIA ALGAL BIOMASS AND/OR RELATED MATERIAL ADMINISTERED TO ANIMALS | DURYEE, ALEXANDER MARSH | 1657 | §103§112 | Final Rejection | — | Pending | Jan 28, 2022 |
| 17410016 | NATURAL FEED COMPOSITION DERIVED FROM FRESH WATER ALGAL CULTURES FOR THE PROMOTION OF ANIMAL GROWTH | XU, QING | 1656 | §103§112 | Final Rejection | 58d overdue | Pending | Aug 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZivo Bioscience Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Nghi V Nguyen has the most, with 1 of Zivo Bioscience Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
